MedTrace Logo

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

NCT00962065 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2011-03-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211 versus a placebo control in subjects with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

LX4211 Low Dose

A low dose of LX4211; daily oral intake for 28 days

DRUG

LX4211 High Dose

A high dose of LX4211; daily oral intake for 28 days

DRUG

Placebo

Matching placebo dosing with daily oral intake for 28 days

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Joel P. Freiman, MD, MPH · Lexicon Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00962065 on ClinicalTrials.gov